During the episode, his finger stick glucose was 381.
He was transferred to [**Hospital1 18**] for evaluation of possible stroke and management of hyperglycemia.
In the ED, the patient was hemodynamically stable, but was noted to have a WBC 15.1, glucose of 443, anion gap of 18, Cr of 1.5 (1.3 in [**4-22**]), and CK ~24,000.
CT head was negative for bleed or mass.
MRI did not show evidence of an acute stroke.
ECHO '[**62**]--> EF 25-25%.
VS: 99.3   148/70   86   20  97%RA HEENT: Seborrheic dermatitis on face.
Pertinent Results: [**2166-6-26**] 12:04PM   WBC-15.1*# RBC-5.28# HGB-15.3# HCT-47.3# MCV-90 MCH-29.1 MCHC-32.5 RDW-13.7 [**2166-6-26**] 12:04PM   PLT COUNT-290 [**2166-6-26**] 12:04PM   GLUCOSE-443* UREA N-35* CREAT-1.5* SODIUM-140 POTASSIUM-4.4 CHLORIDE-100 TOTAL CO2-22 ANION GAP-22* [**2166-6-26**] 01:25PM URINE  BLOOD-LG NITRITE-NEG PROTEIN-30 GLUCOSE-1000 KETONE-TR BILIRUBIN-NEG UROBILNGN-NEG PH-5.0 LEUK-NEG [**2166-6-26**] 01:25PM URINE  RBC-0 WBC-1 BACTERIA-RARE YEAST-NONE EPI-0 [**2166-6-26**] 01:25PM URINE  bnzodzpn-NEG barbitrt-NEG opiates-NEG cocaine-NEG amphetmn-NEG mthdone-NEG [**2166-6-26**] 01:38PM   CK(CPK)-[**Numeric Identifier 23302**]*  [**6-29**] Lab Data: Hematology  WBC RBC Hgb Hct MCV MCH MCHC RDW Plt Ct 13.2* 3.65* 10.6* 32.3* 89 29.2 32.9 14.7 310 Chemistry RENAL & GLUCOSE Glucose UreaN Creat Na K Cl HCO3 AnGap [**2166-6-29**] 06:36AM    131* 31* 1.4* 149* 3.7 113* 27 13 ENZYMES & BILIRUBIN ALT AST LD(LDH) CK(CPK) AlkPhos Amylase TotBili DirBili [**2166-6-29**] 06:36AM    134* 292* 525*   388* 228* 1.5 OTHER ENZYMES & BILIRUBINS Lipase     [**2166-6-29**] 06:36AM    141* CHEMISTRY TotProt Albumin Globuln Calcium Phos Mg UricAcd Iron [**2166-6-29**] 06:36AM      2.6*   8.1* 2.8 2.0  Micro data: Blood cx [**6-27**]: NGTD Urine cx [**6-27**]: NG [**2166-6-27**] 12:13 am SWAB     Site: ANKLE      Source: left ankle decub.
WOUND CULTURE (Preliminary):       MODERATE GROWTH MIXED BACTERIAL FLORA ( >=3 COLONY TYPES) CONSISTENT       WITH SKIN FLORA.
EKG ([**6-26**]): NSR 78 bpm.
The study and the report were reviewed by the staff radiologist.
DR. [**First Name (STitle) 21827**] [**Name (STitle) 21828**] DR. [**First Name (STitle) **] [**Initials (NamePattern5) 3250**] [**Last Name (NamePattern5) 3251**] Approved: SAT [**2166-6-28**] 12:50 PM  RADIOLOGY  Final Report **ABNORMAL!
CT HEAD W/O CONTRAST  [**2166-6-26**] 12:16 PM  CT HEAD W/O CONTRAST  Reason: change in MS  [**Hospital 93**] MEDICAL CONDITION: 83 year old man with REASON FOR THIS EXAMINATION: change in MS CONTRAINDICATIONS for IV CONTRAST: None.
NON-CONTRAST HEAD CT:  Exam compared to prior study of [**2163-10-28**].
There is increased opacification of the maxillary sinus as compared to the previous examination especially on the left.
MRI OF THE BRAIN AND MRA OF THE CIRCLE OF [**Location (un) **]:  TECHNIQUE: Multiplanar T1 and T2W imaging of the brain was performed.
Multiplanar reformatted images and source image data are reviewed.
MRA of the Circle of [**Location (un) 431**] demonstrates flow in both intracranial internal carotid arteries and in the anterior and middle cerebral arteries.There is flow in both intracranial vertebral arteries.
IMPRESSION: MRA of the brain reveals no evidence of infarction or other signal or structural abnormality of the brain.
MRA of the Circle of [**Location (un) 431**] demonstrates flow in the proximal branches of the circulation.
RIGHT UPPER EXTREMITY ULTRASOUND: The right internal jugular, subclavian, axillary, brachial, basilic, and cephalic veins were examined.
Flow, waveforms, compressibility, and augmentation were assessed.
The study and the report were reviewed by the staff radiologist.
MRI did not show evidence of stroke.
A wound culture grew MSSA and Pseudomonas.
The patient will be treated with Lovenox 80 mg SC q 12 hrs x 4 weeks.
Enoxaparin Sodium 80 mg/0.8 mL Syringe Sig: One (1) Subcutaneous Q12H (every 12 hours) for 4 weeks.
The patient may need further titration of his NPH for optimal blood glucose control.
[**First Name8 (NamePattern2) 23305**] [**Name (STitle) **] Where: CC-2 PODIATRY UNIT Phone:[**Telephone/Fax (1) 3153**] Date/Time:[**2166-7-25**] 1:40
